Self-Testing and Self Injectable Devices Market: By Product ; By Devices ; By Application & By Region-Forecast

Self-Testing and Self Injectable Devices Market: By Product (Auto Injectors, BGM, Others); By Devices (Disposables & Reusable, Fillable & Prefilled, Others); By Application (Diabetes, Oncology, Others) & By Region-Forecast (2016-2022)
[Lowest Price Guaranteed: $5,250]


Related Topics: Blood , Diabetes , Personal

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Self-Testing
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email bioportfolio97@gmail.com.

Introduction

Globally, development of efficient and advanced technologies such as the inclusion of micro needles, rise in the awareness among people, increasing government initiatives across the globe, and growing preference of patients as well as physicians toward pain-free drug delivery are the prime growth drivers of the self-testing and self-injectable devices market. In addition, increase in adoption of self-testing and self-injectable devices for peripheral artery diseases, and emerging economies such as China, India and others, will create new opportunities for the self-testing and self injectable devices market. However, higher cost of research and development, and higher cost of interventional devices are the key restraints for the self-testing and self injectable devices market.


Geographically, North America dominated the global self-testing and self injectable devices market, with approximately half of the world’s consumption being done in the U.S. because of higher healthcare expenditure, medical reimbursement facilities, advanced technologies, and huge investments undertaken by prominent as well as new market entrants. Asia Pacific is projected to have the fastest growth, owing to a rapidly increasing aging population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the products, Blood Glucose Monitoring (BGM) has the fastest growing rate in the self-testing and self injectable devices market due to higher prevalence of diabetic patients.

This report identifies the self-testing and self injectable devices market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the self-testing and self injectable devices market.

This report segments the self-testing and self injectable devices market on the basis of product, devices, application, and regional market as follows:

Self-Testing and Self Injectable Devices Market, By Product: Auto Injectors, Blood Glucose Monitoring (BGM), Double Blood Pump Module (DBPM), Insulin Pump, Activity Monitors, Thermometers, Weighing Machines, and Others

Self-Testing and Self Injectable Devices Market, By Devices: Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free, and Auto Injectors

The report has focused study on self-testing and self injectable devices market by basis of application such as: Diabetes, Oncology, Chronic Diseases, Personal Care, and Others

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the self-testing and self injectable devices market. Some of the major companies’ profiles in detail are as follows:

Becton Dickinson & Co.

Baxter International, Inc.

Bayer Crop Science Ltd.

SHL Group

Ypsomed Holding AG

Table of Contents
for Self-Testing and Self Injectable Devices Market: By Product (Auto Injectors, BGM, Others); By Devices (Disposables & Reusable, Fillable & Prefilled, Others); By Application (Diabetes, Oncology, Others) & By Region-Forecast (2016-2022)

  • 1. Self-Testing and Self Injectable Devices Market – Overview

    2. Executive Summary

    3. Self-Testing and Self Injectable Devices Market Landscape

    3.1. Market Share Analysis

    3.2. Comparative Analysis

    3.3. Product Benchmarking

    3.4. End User Profiling

    3.5. Top 5 Financials Analysis

    4. Self-Testing and Self Injectable Devices Market– Forces

    4.1. Drivers

    4.1.1. Development of efficient and advance technologies such as the inclusion of microneedles

    4.1.2. Growing preference of patients as well as physicians toward pain-free drug delivery

    4.2. Restraints

    4.2.1. Higher cost of research and development

    4.3. Opportunities

    4.3.1. Emerging economies

    4.4. Challenges

    4.5. Porter’s Five Forces Analysis

    4.5.1. Bargaining Power of Suppliers

    4.5.2. Bargaining Power of Buyers

    4.5.3. Threat of New Entrants

    4.5.4. Threat of Substitutes

    4.5.5. Degree of Competition

    5. Self-Testing and Self Injectable Devices Market– Strategic Analysis

    5.1. Value Chain Analysis

    5.2. Pricing Analysis

    5.3. Opportunities Analysis

    5.4. Product/Market Life Cycle Analysis

    5.5. Suppliers and Distributors

    6. Self-Testing and Self Injectable Devices Market, By Product

    6.1. Auto Injectors

    6.2. Blood Glucose Monitoring (BGM)

    6.3. Double Blood Pump Module (DBPM)

    6.4. Insulin Pump

    6.5. Activity Monitors

    6.6. Thermometers

    6.7. Weighing Machines

    6.8. Others

    7. Self-Testing and Self Injectable Devices Market, By Devices

    7.1. Disposables & Reusable

    7.2. Fillable & Prefilled

    7.3. Pen

    7.4. Needle Free

    7.5. Auto Injectors

    8. Self-Testing and Self Injectable Devices Market, By Application

    8.1. Diabetes

    8.2. Oncology

    8.3. Chronic Diseases

    8.4. Personal Care

    8.5. Others

    9. Self-Testing and Self Injectable Devices Market, By Geography

    9.1. Europe

    9.1.1. Germany

    9.1.2. France

    9.1.3. Italy

    9.1.4. Spain

    9.1.5. Russia

    9.1.6. U.K.

    9.1.7. Rest of Europe

    9.2. Asia Pacific

    9.2.1. China

    9.2.2. India

    9.2.3. Japan

    9.2.4. South Korea

    9.2.5. Rest of Asia-Pacific

    9.3. North America

    9.3.1. U.S.

    9.3.2. Canada

    9.3.3. Mexico

    9.4. Rest of the World (RoW)

    9.4.1. Brazil

    9.4.2. Rest of RoW

    10. Self-Testing and Self Injectable Devices – Entropy

    10.1. Expansion

    10.2. Technological Developments

    10.3. Merger & Acquisitions, and Joint Ventures

    10.4. Supply- Contract

    11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

    11.1. Becton Dickinson & Co.

    11.2. Baxter International, Inc.

    11.3. Bayer Crop Science Ltd.

    11.4. SHL Group

    11.5. Ypsomed Holding AG

    11.6. Owen Mumford, Ltd.

    11.7. 3M Pharmaceuticals Inc.

    11.8. Johnson & Johnson Limited

    11.9. GlaxoSmithKline plc

    11.10. Novartis AG

    *More than 40 Companies are profiled in this Research Report, Complete List available on Request*

    "*Financials would be provided on a best efforts basis for private companies"

    12. Appendix

    12.1. Abbreviations

    12.2. Sources

    12.3. Research Methodology

    12.4. Bibliography

    12.5. Compilation of Expert Insights

    12.6. Disclaimer

List Of Tables
in Self-Testing and Self Injectable Devices Market: By Product ; By Devices ; By Application & By Region-Forecast

No

Additional Details

Publisher

Publisher Information

Reference

80665 | HCR 0718

Report Format

PDF

 Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
01 Aug 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
01 Aug 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Market Access in the EU5 – a comparative overview
IntroductionThe sustained and challenging economic environment in the EU has impacted – and is impac...
01 Aug 2013 by FirstWord Pharma USD $336 (normally
USD $395)
More Info
SAVE 15% today! Physician Views: Post ADA view on key diabetes market developments
ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
01 Jul 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
01 Jul 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
01 Jun 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
01 Jun 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Surveying Physician Uptake of Mobile Devices and Apps
IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
01 Oct 2012 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Market Access: Communicating Value Stories to Payers
IntroductionThroughout the EU, reimbursement decisions are increasingly decentralised, making the pr...
01 Apr 2012 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Gauging the Biosimilar Effect: will the market boom or bust?
IntroductionIt was supposed to be the “epoch of biosimilars”, or drugs that copied existing biologic...
01 Jan 2012 by FirstWord Pharma USD $761 (normally
USD $895)
More Info

We Stock...